Floatz logo

Therapeutic Asset Ratings

13,150 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Sirolimus
Epilepsy
Xuanwu Hospital, BeijingP2B (56)
Sirolimus
Myelofibrosis
Masonic Cancer Center, University of MinnesotaP2B (56)
Sry-Box Transcription Factor 2
Her2-Receptor Negative Breast Cancer
University of WashingtonP2B (56)
Tafasitamab
Primary Mediastinal Large B-Cell Lymphoma
Paolo Caimi, MDP2B (56)
Tagraxofusp
Acute Myeloid Leukemia
Jacqueline Garcia, MDP2B (56)
Talazoparib
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (56)
Tamoxifen
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (56)
Tarlatamab
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (56)
Tebapivat
Sickle Cell Disease
Agios Pharmaceuticals, Inc.P2B (56)
Temsirolimus
Plasma Cell Myeloma
Canadian Cancer Trials GroupP2B (56)
Teonanacatl
Chronic Pain Syndrome
Yale UniversityP2B (56)
Theprubicin
Triple-Negative Breast Carcinoma
Xijing HospitalP2B (56)
Thiotepa
Hematopoietic And Lymphoid Cell Neoplasm
St. Jude Children's Research HospitalP2B (56)
TIL
Colorectal Cancer
City of Hope Medical CenterP2B (56)
Tislelizumab
Prostate Cancer
Shanghai Changzheng HospitalP2B (56)
Tislelizumab
Pancreatic Adenocarcinoma
Indaptus Therapeutics, IncP2B (56)
Tislelizumab
Sarcoma
HiFiBiO TherapeuticsP2B (56)
Tocilizumab
Melanoma
University of Southern CaliforniaP2B (56)
Toripalimab
Clear Cell Renal Carcinoma
RenJi HospitalP2B (56)
Toripalimab
Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.P2B (56)
Trametinib
Uveal Melanoma
Alliance for Clinical Trials in OncologyP2B (56)
Trametinib
Non-Hodgkin Lymphoma
OHSU Knight Cancer InstituteP2B (56)
Trametinib
Colorectal Cancer
Xynomic Pharmaceuticals, Inc.P2B (56)
Trametinib
Exocrine Pancreatic Carcinoma
University of UtahP2B (56)
Trastuzumab
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (56)
Showing 2526 to 2550 of 13,150 assets
PreviousPage 102 of 526Next